World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Keith Berelowitz, MSc
Director of Operations

A scientist by training, Keith has worked in clinical research (academic and commercial) for over 22 years, having spent the majority of that period working for Richmond Pharmacology. In his role as Director of Operations at Richmond Pharmacology he is focused on the commercial management of the studies we conduct, the efficiency of the company’s functions and oversight of the healthy volunteer and patient recruitment division, integral to the studies conducted by Richmond Pharmacology.

Having played an operational role in over 250 studies, across the commercial, project and recruitment related management of these studies, his specialist area of interest has focused on the assessment and delivery of early and late phase patient trials in a Phase I environment. Keith has worked with a number of sponsors advising them on the viability of conducting such trials within the UK, a number of which have gone on to be conducted successfully with Richmond Pharmacology.

Keith is a member of the National Research Ethics Service Phase 1 Advisory Group (Health Research Authority, UK), Vice Chair of the Fulham Research Ethics Committee and a member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK) and one of the UK representative of the EUCROF Extended Executive Board

Back to experts

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more